Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SmithKline/Glaxo Denavir team approach could work for cold sore cream OTC switch.

This article was originally published in The Tan Sheet

Executive Summary

SMITHKLINE, GLAXO DENAVIR TEAM APPROACH FOR Rx-TO-OTC SWITCH of SmithKline's topical cold sore treatment could be one outcome of the proposed merger between Glaxo Wellcome and SmithKline Beecham. At a September 1996 analysts meeting, SmithKline CEO Jan Leschly said the company would pursue the switch of Denavir immediately upon receiving Rx approval, which was granted by FDA on Sept. 24, 1996, and SmithKline's consumer healthcare products unit markets the Rx product ("The Tan Sheet" Sept. 30, 1996, p. 14). The two companies announced they were in merger talks Jan. 30, signaling the end to discussions between SmithKline Beecham and American Home Products.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel